A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers

NCT02797795 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer
Solid Tumors

Interventions

DRUG: NEV801

Sponsor

Neovia Oncology Ltd.